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HIV-seronegative Cameroonians with exposure to
nonhuman primates were tested for simian immunodefi-
ciency virus (SIV) infection. Seroreactivity was correlated
with exposure risk (p<0.001). One person had strong
humoral and weak cellular immune reactivity to SIVcol pep-
tides. Humans are exposed to and possibly infected with
SIV, which has major public health implications.
T
wo major public health priorities are ensuring the safe-
ty of the blood supply and preventing the emergence
of new infectious diseases. Phylogenetic evidence shows
that HIV-1 and HIV-2 were introduced into humans
through independent cross-species transmission of simian
immunodeficiency virus (SIV) strains from distinct, natu-
rally infected, nonhuman primate (NHP) hosts. HIV-1
groups M, N, and O are believed to have arisen as 3 sepa-
rate cross-species transmissions from chimpanzees, and
each of the HIV-2 subtypes A–G was the result of inde-
pendent transmissions from sooty mangabeys (Cercocebus
atys) to humans. While laboratory exposure to NHPs has
caused infections with SIV (1–3), no direct evidence has
been seen of ongoing exposure to or infection with SIV in
natural settings. Nevertheless, hunting and butchering wild
NHPs for food, which expose humans to NHP blood and
body fluids, are widespread in sub-Saharan Africa and may
lead to ongoing transmission from any of the 33 species of
NHP that are known to harbor their own unique SIV
strains. Since ongoing lentivirus emergence would be of
substantial importance to global public health, we looked
for evidence of SIV in a unique collection of plasma from
persons with known levels of exposure to the blood and
body fluids of NHPs (3).
The Study
No commercial serologic assays can detect SIV infec-
tions in humans, and published assays for this purpose are
not designed to detect a wide range of divergent SIV
strains. To determine whether humans are infected with
SIV, we developed a sensitive and specific SIV multiple
antigenic peptide–based enzyme immunoassay (SMAP-
EIA) for detecting env IDR (immunodominant region of
gp41/gp36) and V3 antibodies to all of the SIV lineages for
which env sequences were available, specifically SIVsm,
SIVagm, SIVsyk, SIVcpz, SIVlhoest/SIVsun, SIVcol,
SIVmnd and SIVdrl, SIVrcm, and SIVdeb (4). The SMAP-
EIA also detects other SIV strains not represented by spe-
cific SIV lineage–based peptides.
This study was carried out under an approved protocol
in accordance with guidelines set forth by the Centers for
Disease Control and Prevention (CDC). We tested plasma
samples from Cameroon that were seronegative for HIV-1
and HIV-2 by EIA. Cameroon has extensive HIV-1 genet-
ic diversity, and rural bushmeat hunting is common (2).
Plasma from 3 different groups in Cameroon was exam-
ined: 1) persons in remote villages who reported a high
level of exposure to bodily fluids of NHPs through hunting
NHPs, butchering NHPs, or keeping wild NHP pets (n =
76) (2); 2) persons from the same villages who reported a
low level of NHP exposure (n = 77) (2); and 3) persons
from a general population (n = 1,071) from urban and rural
areas in Cameroon where people may handle NHP meat
but are unlikely to have repeated contact with the blood or
body fluids of freshly killed animals. We tested the serore-
activity of these small-volume samples by using our
SMAP-EIA. Of the samples that were reactive (optical
density [OD] >1.000) to >1 of a panel of 9 SIV IDR MAPs
(Figure 1), 17.1% were seroreactive in the high exposure
group, 7.8% in the low exposure group, and 2.3% in the
general group. The higher the risk for exposure to fresh
NHP blood and body fluids, the greater the frequency of
reactivity (p<0.001).
Only 1 of the plasma samples, with an IDR OD >1, also
reacted strongly to the homologous V3 peptide. This sam-
ple, which was from our general population, reacted to the
SIVcol (Colobus guereza) MAPs in both IDR (OD =
1.250) and V3 (OD = 1.798). Since frozen viable cells
were available from this person, we performed an interfer-
on-γ enzyme-linked immunospot (ELISPOT) assay to
determine whether peripheral blood lymphocytes (PBLs)
from this person recognized SIVcol peptides from C.
guereza. Since no information is available about T-cell epi-
topes within the SIVcol genome, and the SIV strains from
C. guereza are highly divergent from all known SIV
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(16-mers overlapping by 10) across the gag gene, on the
basis of the only available Colobus sequence (5). Pools of
10 peptides were each tested in the ELISPOT assay. Low
levels of T-cell reactivity to pools 71–80 and 81–86 of the
gag peptides (10× and 5× background, respectively, and
>25 spots/106 PBLs) and env V3 and IDR peptides (9× and
6× background, respectively) were observed with unfrac-
tionated PBLs (Figure 2). No reactivity was observed in
PBLs from an HIV-1–seronegative African donor used as
a negative control. Polymerase chain reaction (PCR) and
reverse transcription–PCR amplifications from proviral
DNA lysates, plasma from this sample, and cells from
stimulated ELISPOT wells were performed with pol
primers originally used to identify the C. guereza sequence
(5) and with other primers specifically designed from the
published C. guereza sequence. Despite a strong humoral
(env IDR and V3) response and weak cellular (gag)
immune reactivity (in the range of ELISPOT results
reported from sex workers who were highly exposed to
HIV but seronegative), we were unable to amplify any
SIVcol nucleic acids. Seroreactivity without PCR amplifi-
cation has been documented in those with occupational
SIV exposures (1,2). Therefore, seroreactivity to SIVcol in
this person may reflect exposure to nonviable or defective
SIVcol, a nonproductive or cleared infection, or sequester-
ing of virus in lymphatic tissues. 
Conclusions
Our data, taken together with previous reports of high
prevalence of SIV in NHP bushmeat (6) and high levels of
NHP exposure (3), offer new evidence that persons who
hunt and butcher wild NHPs are subject to ongoing expo-
sure and potential infection with SIV. In a study of 16 SIV
isolates from 5 different primate lineages, 12 were capable
of infecting human monocyte-derived macrophages, and
11 were capable of replicating in human peripheral blood
mononuclear cells (7), although cell tropism does not nec-
essarily predict virus pathogenicity. Productive crossover
infections may occur in low numbers in remote areas of
Africa, but because of low population density and isola-
tion, they do not have the opportunity to become epidemic
strains and instead become dead-end infections. Ongoing
transmission events may also be missed because serologic
assays for detecting a broad range of SIVs are lacking or
because monitoring is insufficient in populations with high
levels of exposure to NHP blood and body fluids. We also
have reason to believe that the frequency of SIV exposure
and possible infection has increased during recent decades
because of a combination of factors that have increased
levels of NHP hunting (3); these factors include increased
access to firearms, increased access to undisturbed NHP
habitat from new logging roads, and increased demand for
bushmeat in logging camps and rural and urban markets.
New roads increase travel, increasing the probability that
productive crossover SIV infections will emerge. Further
surveillance for new, potentially successful, cross-species
lentivirus transmission in Africa is needed to ensure a safe
blood supply and prevent the spread of novel, emerging
HIV infections.
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Figure 1. Simian immunodeficiency (SIV) multiple antigenic pep-
tide–enzyme immunoassay (SMAP-EIA) seroreactivity trends to
SIV immunodominant region (IDR) peptides in HIV-seronegative
Cameroonian population groups with different levels of exposure
(high exposure [HE], low exposure [LE], or general [G]) to nonhu-
man primates. OD, optical density. χ2 linear trend 48.166, p<0.001.
Figure 2. Interferon-γ enzyme-linked immunospot reactivity stimu-
lated with SIVcol peptides from the env and gag regions in periph-
eral blood lymphocytes (PBLs) from a person seropositive for both
the SIVcol V3 and immunodominant region (IDR) peptides and a
seronegative person from Africa (both men). To include both assays
in a single graph, the number of spots per 106 PBLs for each pool
of gag peptides was divided by the number of spots per 106 PBLs
in the medium control. This value was expressed as the level of
reactivity above background; i.e., the value 2 on the y-axis stands
for 2× the number of spots in the negative (medium) control.Acknowledgments
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